Rapid Sequence Intubation Medication Regimen

Medication Selection

The American College of Critical Care Medicine recommends a sedative-hypnotic induction agent (etomidate or ketamine) followed by a neuromuscular blocking agent (either succinylcholine or rocuronium) for rapid sequence intubation in critically ill adults 1, 2
A sedative-hypnotic induction agent must be administered before the neuromuscular blocking agent to prevent awareness during paralysis, as recommended by the Critical Care Medicine society 3
Etomidate (0.3 mg/kg IV) is preferred in hemodynamically unstable patients due to its favorable hemodynamic profile, according to the Critical Care Medicine guidelines 4
Ketamine (1-2 mg/kg IV) is an alternative first-line agent with sympathomimetic properties that help maintain hemodynamic stability, as suggested by the Praxis Medical Insights 3

Neuromuscular Blocking Agent Selection

An NMBA should be administered when a sedative-hypnotic induction agent is used for intubation, as recommended by the Critical Care Medicine society 1, 2
Succinylcholine (1-1.5 mg/kg IV) is the first-line NMBA when no contraindications exist, according to the Critical Care Medicine guidelines 1, 2
Rocuronium (0.9-1.2 mg/kg IV) is an alternative when succinylcholine is contraindicated, as recommended by the Critical Care Medicine society 1, 2

Preoxygenation and Positioning

Position the patient in semi-Fowler position (head and trunk inclined) during RSI to improve first-pass intubation success and reduce risk of aspiration, as recommended by the Critical Care Medicine society 1, 5
Use high-flow nasal oxygen (HFNO) when challenging laryngoscopy is anticipated, according to the Critical Care Medicine guidelines 1, 5
Use noninvasive positive pressure ventilation (NIPPV) in patients with severe hypoxemia (PaO2/FiO2 < 150), as suggested by the Critical Care Medicine society 1, 5

Induction Agent Selection

No mortality difference has been demonstrated between etomidate and other induction agents in critically ill patients, according to the Critical Care Medicine guidelines 4
Etomidate may cause transient adrenal suppression, but corticosteroid administration following etomidate is not recommended, as suggested by the Critical Care Medicine society 1, 4

NMBA Selection

Both succinylcholine and rocuronium provide excellent intubating conditions, according to the Critical Care Medicine guidelines 1, 2
When using high-dose rocuronium (≥0.9 mg/kg), sugammadex should be available for reversal if needed, as recommended by the Anaesthesia society 6

Recommended Dosage for Ketamine and Rocuronium in Rapid Sequence Intubation

Ketamine Dosing

Ketamine should be dosed at 1-2 mg/kg IV for RSI in critically ill adult patients 7, 8
For patients with cardiovascular compromise, consider using the lower end of the dosing range (1 mg/kg) to minimize hemodynamic effects while still achieving adequate sedation 8

Rocuronium Dosing

Rocuronium should be administered at 1.0-1.2 mg/kg IV for RSI to ensure optimal intubating conditions 8, 9
Rocuronium should be given as early as practical after induction to minimize apnea time and risk of patient coughing 8

Timing Considerations

After administering ketamine and rocuronium, ensure full neuromuscular blockade before attempting intubation 8
Wait at least 60 seconds after rocuronium administration before attempting intubation, or use a peripheral nerve stimulator to confirm adequate blockade 8

Special Considerations

In patients at risk for cardiovascular instability, ketamine may be preferred over other induction agents due to its relative hemodynamic stability 7
When using high-dose rocuronium, consider having sugammadex available for reversal if needed in a "can't intubate, can't ventilate" scenario 10
Ensure vasopressors are immediately available for managing potential hypotension during RSI 8

Pitfalls and Caveats

In critically ill patients with depleted catecholamine stores, ketamine may paradoxically cause hypotension despite its sympathomimetic properties 11
Ensure full neuromuscular blockade before attempting intubation to prevent coughing or movement that could increase the risk of aspiration 8

Etomidate Dosage and Side Effects in Adults

Dosage and Administration

Higher doses of etomidate (>0.3 mg/kg) have been associated with increased risk of respiratory depression, particularly in older patients 12, 13

Potential Side Effects and Precautions

Vomiting is reported in approximately 4-10% of patients receiving etomidate 12, 13
Oxygen desaturation requiring supplemental oxygen has been reported in approximately 5% of patients, with higher risk in those >55 years receiving doses ≥0.23 mg/kg 12

Important Clinical Pearls

Monitor for respiratory depression, particularly in older patients or those receiving doses at the higher end of the recommended range 12, 13

Ketamine vs Etomidate for Intubation in Critically Ill Patients

Comparative Efficacy and Safety

Both ketamine and etomidate provide adequate intubating conditions with minimal hemodynamic effects, but their specific properties differ significantly, with ketamine offering relative hemodynamic stability through sympathomimetic properties 14
Etomidate has traditionally been valued for its favorable hemodynamic profile but carries significant concerns regarding adrenal suppression, particularly in septic patients 15
The Society of Critical Care Medicine (SCCM) guidelines suggest there is no significant difference between etomidate and other induction agents with respect to mortality or vasopressor use, based on moderate quality evidence 14, 15

Patient-Specific Considerations

Pediatric guidelines explicitly recommend against etomidate use in septic shock due to adrenal suppression concerns, and instead recommend ketamine with atropine pretreatment and benzodiazepine post-intubation 16, 17
Ketamine should be strongly preferred over etomidate in patients with sepsis or septic shock, according to pediatric guidelines 16, 17

Practical Administration Guidelines

Both ketamine and etomidate should be followed by an appropriate neuromuscular blocking agent for optimal intubating conditions, as recommended by the Society of Critical Care Medicine 14

Etomidate Induction Dosing and Safety Considerations

Dose Modifications for Specific Populations

In hemodynamically compromised patients, consider reducing the dose to 0.15 mg/kg to minimize cardiovascular effects while maintaining adequate sedation 18
Higher doses (>0.3 mg/kg) are associated with increased risk of respiratory depression, particularly in patients over 55 years of age 19

Clinical Context: Rapid Sequence Intubation

The Society of Critical Care Medicine recommends etomidate 0.3 mg/kg IV as a first-line induction agent due to its favorable hemodynamic profile 20, 21
The 0.2-0.3 mg/kg dose range used in RSI studies showed no increased mortality compared to other induction agents (OR 1.17; 95% CI 0.86-1.60) 18

Important Safety Considerations

Oxygen desaturation requiring supplemental oxygen occurs in approximately 5% of patients, with higher risk in those receiving doses ≥0.23 mg/kg 19

Critical Pitfall to Avoid

Do not use higher doses (>0.3 mg/kg) in elderly patients or those with respiratory compromise, as doses of 0.23 mg/kg or higher in patients over 55 years were associated with oxygen desaturation requiring bag-assisted ventilation in 4 of 5 cases 19
When hemodynamic instability is present, err on the side of lower dosing (0.15-0.2 mg/kg) rather than standard dosing 18

Adrenal Suppression Controversy

Corticosteroid administration following etomidate is NOT recommended, as multiple RCTs showed no mortality benefit 22
The clinical significance of this biochemical adrenal suppression remains unclear, as overall mortality was not increased in meta-analyses of critically ill patients 20

Ketamine for Delayed Sequence Intubation

Introduction to Ketamine Use

The Society of Critical Care Medicine recommends ketamine or etomidate as first-line induction agents for delayed sequence intubation (DSI), with ketamine being preferred due to its ability to preserve spontaneous respirations and airway reflexes, allowing for safe preoxygenation in agitated patients 23

Practical DSI Protocol with Ketamine

Administer ketamine 1-2 mg/kg IV for dissociative sedation, with the option to use high-flow nasal oxygen (HFNO) or noninvasive positive pressure ventilation (NIPPV) for preoxygenation, as recommended by guidelines from the field of anaesthesia 24
The American College of Critical Care Medicine states that ketamine is a suitable option for DSI due to its sympathomimetic properties, which can help maintain hemodynamic stability during the procedure 23

Comparative Safety Profile

The Society of Critical Care Medicine guidelines found no significant mortality difference between etomidate and ketamine in general critically ill populations undergoing standard rapid sequence intubation (RSI), but recent evidence suggests ketamine may reduce mortality in critically ill adults 23

Rapid Sequence Intubation Medication Dosing

Weight-Based Dosing Considerations

The American Heart Association, as published in Circulation, recommends using actual body weight, not ideal body weight, for RSI medications, as succinylcholine requires dosing based on actual body weight for non-resuscitation medications 25
The American Heart Association, as published in Circulation, suggests that dosing succinylcholine based on actual body weight rather than ideal body weight is critical for optimal intubating conditions 25

Recommended Medication Regimen

Neuromuscular Blocking Agent: Succinylcholine

The American Heart Association, as published in Circulation, recommends a dose of 1.5 mg/kg IV based on actual body weight for succinylcholine, which is approximately 190 mg total for a 127 kg patient 25

Rapid Sequence Intubation: Etomidate and Succinylcholine Dosing

Standard Dosing Recommendations

The American Academy of Pediatrics recommends administering etomidate 0.3 mg/kg IV followed immediately by succinylcholine 1-2 mg/kg IV (1.5 mg/kg for infants <6 months) for RSI 26, 27

Succinylcholine Dosing

The standard IV dose of succinylcholine is 1-2 mg/kg (use 2 mg/kg for infants <6 months) 26, 27
The intramuscular dose of succinylcholine is 4 mg/kg (5 mg/kg for infants <6 months) if IV access is unavailable 26, 27
The onset of action of succinylcholine is 30-45 seconds IV, 3-5 minutes IM 26, 27
The duration of action of succinylcholine is 5-10 minutes 26, 27

Essential Premedication

Atropine 0.02 mg/kg (minimum 0.1 mg, maximum 1 mg) should be administered before succinylcholine to prevent bradycardia or asystole, particularly in pediatric patients 26, 27

Critical Contraindications to Succinylcholine

Succinylcholine is contraindicated in patients with a previous history of malignant hyperthermia, severe burns or crush injury, spinal cord injury, or risk of hyperkalemia (particularly in boys <9 years old) 26, 27

Dosing Pitfalls to Avoid

Doses of etomidate ≥0.23 mg/kg in patients >55 years were associated with oxygen desaturation requiring bag-assisted ventilation 28

Pediatric-Specific Considerations

The American Academy of Pediatrics recommends a succinylcholine dose of 2 mg/kg IV for infants <6 months, 1-2 mg/kg for older children 26, 27
Atropine 0.02 mg/kg should always be administered before succinylcholine in pediatric patients to prevent bradycardia 26, 27

Safety Monitoring Requirements

Suction equipment and age-appropriate intubation equipment should be immediately available during RSI 26, 27

Rapid Sequence Intubation – Evidence‑Based Dosing Recommendations

Neuromuscular Blocking Agents (Adults)

Succinylcholine administered at 1–1.5 mg/kg intravenously is the first‑line neuromuscular blocker for rapid‑sequence intubation in adults, producing paralysis within 30–45 seconds and lasting 5–10 minutes. 29

Neuromuscular Blocking Agents (Pediatrics)

In children, succinylcholine dosing is weight‑based: 2 mg/kg IV for infants younger than six months, 1–2 mg/kg IV for older children, and 4–5 mg/kg IM when intravenous access is unavailable. 29
Pediatric patients should receive atropine 0.02 mg/kg (minimum 0.1 mg, maximum 1 mg) before succinylcholine to prevent bradycardia or asystole. 29
Succinylcholine is contraindicated in individuals with a history of malignant hyperthermia, severe burns or crush injury, spinal cord injury, or conditions predisposing to hyper‑kalemia (particularly male children < 9 years). 29

Induction Agents (Pediatrics)

Etomidate 0.3 mg/kg IV is recommended for pediatric rapid‑sequence intubation, followed immediately by a neuromuscular blocker. 29

Safety Measures for Elderly Patients

In patients older than 55 years, etomidate doses >0.3 mg/kg are associated with oxygen desaturation that frequently necessitates bag‑valve‑mask ventilation; therefore, lower dosing (≤0.3 mg/kg) and immediate availability of ventilation support are advised. 29

Medication‑Assisted Pre‑oxygenation (All Ages)

For agitated or uncooperative patients unable to tolerate conventional pre‑oxygenation, a ketamine regimen of 1 mg/kg IV (titrated with additional 0.5 mg/kg doses to a mean total of 1.4 mg/kg) given three minutes before the neuromuscular blocker increases mean arterial oxygen saturation by ≈8.9 % (95 % CI 6.4–10.9 %). 30

Awareness Risk and Mitigation in Rapid Sequence Intubation with Rocuronium and Ketamine

Incidence of Explicit Recall

The incidence of explicit recall of intubation in patients receiving rocuronium and ketamine for rapid‑sequence intubation is approximately 2.6 % in emergency intubations, and this rate can be substantially reduced when protocolized post‑intubation analgosedation is implemented immediately after the procedure (observational study) 31.

Pharmacologic Mismatch Leading to Awareness

Rocuronium provides neuromuscular blockade lasting 30–60 minutes, whereas ketamine’s dissociative effects wear off much sooner, creating a window in which patients may be paralyzed but inadequately sedated (pharmacologic rationale) 31.
The longer duration of rocuronium compared with succinylcholine (5–10 minutes) may prevent patient movement that would otherwise alert staff to provide additional sedation, making delayed analgosedation a particular concern (pharmacologic comparison) 31.

Critical Mitigation Strategies

Institutions should implement protocolized post‑intubation analgosedation immediately after RSI with rocuronium, ideally involving a clinical pharmacist, to prevent the awareness window that occurs when paralysis outlasts sedation (guideline recommendation) 31.
A dedicated team member—preferably a clinical pharmacist—should be assigned to manage the timing of post‑intubation analgosedation (operational recommendation) 31.
Standardized order sets that automatically trigger sedation protocols after rocuronium administration should be used to ensure timely analgesia and sedation (process recommendation) 31.

Sedation Dosing Considerations

The initial ketamine dose of 1–2 mg/kg does not provide adequate sedation throughout the entire duration of rocuronium‑induced paralysis; ketamine’s dissociative effects dissipate well before the neuromuscular blockade resolves, creating a high‑risk period for awareness if additional sedation is not promptly administered (clinical caution) 31.

Comparative Context with Succinylcholine

Studies examining awareness have not shown differences in incidence between succinylcholine and rocuronium when optimal analgosedation is prospectively provided by the healthcare team (comparative study) 31.
Observational data suggest that rocuronium may delay the provision of post‑intubation analgosedation compared with succinylcholine, likely because the absence of patient movement fails to cue staff (observational finding) 31.